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Abstract
Aim To determine participant knowledge and reporting of hypoglycaemia in the non-interventional Hypoglycaemia
Assessment Tool (HAT) study.
Methods HAT was conducted in 24 countries over a 6-month retrospective/4-week prospective period in 27 585 adults
with Type 1 or insulin-treated Type 2 diabetes mellitus. Participants recorded whether hypoglycaemia was based on
blood glucose levels, symptoms or both.
Results Hypoglycaemia rates were consistently higher in the prospective compared with the retrospective period. Most
respondents (96.8%Type 1 diabetes; 85.6%Type 2 diabetes) knew the American Diabetes Association/European Association
for the StudyofDiabetes hypoglycaemiadefinition, but therewere regional differences in theuseof bloodglucosemeasurements
and/or symptoms to define events. Confirmed symptomatic hypoglycaemia rates were highest in Northern Europe/Canada
forType1diabetes (63.9events/year) and inEasternEurope forType2diabetes (19.4events/year), and lowest inSouthEastAsia
(Type 1 diabetes: 6.0 events/year; Type 2 diabetes: 3.2 events/year). Unconfirmed symptomatic hypoglycaemia rates were
highest in Eastern Europe for Type 1 diabetes (5.6 events/year) and South East Asia for Type 2 diabetes (4.7 events/year),
and lowest for both in Russia (Type 1 diabetes: 2.1 events/year; Type 2 diabetes: 0.4 events/year). Participants in Latin
America reported the highest rates of severe hypoglycaemia (Type 1 diabetes: 10.8 events/year; Type 2 diabetes 3.7 events/
year) and severe hypoglycaemia requiring hospitalization (Type 1 diabetes: 0.56 events/year; Type 2 diabetes: 0.44 events/
year). The lowest rates of severe hypoglycaemia were reported in South East Asia (Type 1 diabetes: 2.0 events/year) and
Northern Europe/Canada (Type 2 diabetes: 1.3 events/year), and the lowest rates of severe hypoglycaemia requiring
hospitalizationwere inRussia (Type 1 diabetes: 0.15 events/year; Type 2 diabetes: 0.09 events/year). The blood glucose cut-
off used to define hypoglycaemia varied between regions (Type 1 diabetes: 3.1–3.6mmol/l; Type 2 diabetes: 3.5–3.8mmol/l).
Conclusions Under-reportingofhypoglycaemiarates in retrospective recall andregional variations inparticipantdefinitions
of hypoglycaemia may contribute to the global differences in reported rates. Discrepancies between participant definitions
and guidelines may highlight a need to redefine hypoglycaemia criteria. (Clinical Trials Registry No: NCT01696266).
Diabet. Med. 35, 1232–1241 (2018)
Introduction
Insulin therapy, the most effective treatment for lowering
blood glucose [1], comes with the attendant risk of hypo-
glycaemia, which may prevent people with diabetes from
achieving glycaemic control [2,3]. Position statements from
the American Diabetes Association (ADA) and European
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Association for the Study of Diabetes (EASD) recommend a
patient-centred approach with individualized glycaemic tar-
gets to minimize hypoglycaemia [4,5].
Despite the potentially serious consequences, it remains
unclear how people with diabetes understand and define
hypoglycaemia [6]. Hypoglycaemia definitions, including
symptomatic vs. blood glucose measured and the use of
different blood glucose cut-off points, vary in different
studies, regions and guidelines [7–9]. For example, the ADA
and American Academy of Clinical Endocrinologists con-
sider blood glucose values ≤ 3.9 mmol/l as hypoglycaemia
[5,8]; the International Hypoglycaemia Study Group and
ADA/EASD recommend reporting all events with blood
glucose < 3.0 mmol/l [10]; the Canadian Diabetes Associa-
tion use a cut-off of 4 mmol/l [7]; whereas a cut-off of
3.5 mmol/l has been used to define clinically meaningful
hypoglycaemia [6]. The use of different hypoglycaemia
definitions has a major effect on reported hypoglycaemia
incidence [10–12].
The Hypoglycaemia Assessment Tool (HAT) study exam-
ined the incidence and impact of hypoglycaemia in a large,
insulin-treated global population with Type 1 or Type 2
diabetes mellitus in developed and developing countries. The
epidemiological observational study covered a 6-month
retrospective and 4-week prospective period. Baseline char-
acteristics and overall hypoglycaemia rates from the prospec-
tive period, published previously, showed that rates were
high compared with previous studies and that there were
large differences between regions [13].
Our aim, in this post-hoc analysis, was to determine
participants’ knowledge, definitions and reporting of hypo-
glycaemia in the HAT study population, and to compare
data from retrospective and prospective study periods, and
from different geographic regions of the global study
population.
Materials and methods
Study design and participants
Participant selection and study design have been reported in
the primary article [13]. Briefly, consecutive participants
were enrolled during routine clinical consultation if they had
Type 1 or Type 2 diabetes and were treated with insulin for
> 12 months, were ≥ 18 years of age at baseline and
provided informed consent.
HAT was a non-interventional, multicentre, 6-month ret-
rospective/4-week prospective investigation of hypoglycaemic
events [13] (Appendix S1; Fig. S1), conducted during 2012–
2013 at 2004 sites in 24 countries across six regions (Eastern
Europe: Bulgaria, Croatia, Czech Republic, Hungary, Poland,
Romania, Serbia, Slovakia and Slovenia; Latin America:
Argentina and Mexico; Middle East: Israel, Lebanon and
Saudi Arabia; Northern Europe/Canada: Austria, Canada,
Denmark, Finland, Germany, The Netherlands and Sweden;
Russia: Russian Federation; South East Asia: India and
Malaysia). The study was registered at clinicaltrials.gov
(NCT01696266), conducted in accordance with the Declara-
tion of Helsinki 2004 [14] and ICH Good Clinical Practice
[15], and approved by country-specific regulatory agencies.
All study materials were translated into local languages using
independent forward and back-translation to secure compa-
rability, and data obtained were translated back into English
for analysis. Participants were excluded from the study
because of non-ambulatory status and illiteracy, or other
issues resulting in an inability to complete a written question-
naire. No incentives were provided to study participants.
Assessments
HATwas conducted using a two-part self-assessment question-
naire (part 1: baseline data and history of any hypoglycaemia
over the previous 4 weeks, or 6 months for severe hypogly-
caemia; part 2: hypoglycaemia during the 4-week prospective
period) and participant diaries over the 4-week prospective
study period (Appendix S1). For all but severe hypoglycaemia,
retrospective rates were based on the 4 weeks pre-baseline and
prospective rates on the 4 weeks post baseline. For severe
hypoglycaemia, retrospective rates were based on the 6 months
pre-baseline and prospective rates on the 4 weeks post baseline.
In the part 1 questionnaire, participants were asked at what
blood glucose level they considered a hypoglycaemic event to
have occurred. For the prospective period (part 2), a participant
diary was used to record whether hypoglycaemia was based on
bloodglucose levels, symptomsofhypoglycaemiaorboth.Blood
glucose was self-measured and self-reported by participants.
Confirmed hypoglycaemia definition
Hypoglycaemia categories recorded in the questionnaire
included non-severe hypoglycaemia (a hypoglycaemic event
What’s new?
• This analysis of data from the Hypoglycaemia Assess-
ment Tool (HAT), a prospective study on hypogly-
caemia in 27 585 adults with Type 1 and Type 2
diabetes mellitus across 24 countries, investigated
hypoglycaemia frequency and definitions in a large
population that included countries/regions with little or
no other hypoglycaemia data.
• Hypoglycaemia rates were consistently higher in the
prospective vs. retrospective period across regions
and definitions of hypoglycaemia varied between
regions.
• Under-reporting and variations in the definitions of
hypoglycaemia may result in global differences in
reported rates.
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as judged by the participant and managed by the participant
alone), severe hypoglycaemia [defined as (a) requiring third-
party assistance, based on the ADA definition [16], or (b)
leading to hospital admission] and nocturnal hypoglycaemia
(any event occurring between midnight and 06:00 h). A
combined measure of any hypoglycaemia, based on the sum
of all individual hypoglycaemic events of any category, was
calculated based on diary and questionnaire entries. Con-
firmed hypoglycaemia was defined as a blood glucose
recording < 3.9 mmol/l in the participant diary.
Hypoglycaemia awareness
The degree of hypoglycaemia awareness was indicated by
responses to the question ‘Do you have symptoms when you
have a low sugar level?’, where ‘Always’ denotes normal,
‘Usually’ denotes impaired, and ‘Occasionally’ and ‘Never’
denote severely impaired awareness [17].
Statistical analysis
Hypoglycaemia rates are reported in episodes per year, with
95% confidence intervals (CIs). Differences in the estimated
rates between the prospective and retrospective periods were
calculated using a negative binomial regression model,
adjusted for country and including a single binary covariate
for period (4 weeks pre-baseline, 4 weeks post baseline),
specifying a log-transformed exposure time offset term and
using robust standard errors to adjust for repeated measure-
ments on individuals and the potential dependence between
participants sharing the same site (site-level clustering).
Blood glucose measurements, for the blood sugar levels
that participants consider to be a hypoglycaemic event
overall, and by which participants provided values consistent
with standard definitions (≤ 3.9 mmol/l), were summarized
descriptively.
Results
Study population
Overall, 85% of those invited to participate in the HAT
study accepted the invitation, with 27 585 people partici-
pating and completing the part 1 questionnaire (Type 1
diabetes: 8022; Type 2 diabetes: 19 563). The part 2
questionnaire and participant diary were completed by
92.5% and 85.7% of participants, respectively. The baseline
characteristics of the study population have been reported
previously [13] and are summarized in the online Supporting
Information (Appendix S1; Tables S1 and S2).
Hypoglycaemia rates: retrospective vs prospective periods
Higher estimated overall (any) hypoglycaemia rates were
reported prospectively vs. retrospectively for the overall
study population and in all regions for both Type 1 and Type
2 diabetes, except for Type 1 diabetes in South East Asia and
Type 2 diabetes in the Middle East. The greatest increase in
any hypoglycaemia incidence reported for the retrospective
vs. prospective periods was in Latin America for both Type 1
and Type 2 diabetes.
Retrospectively, 83.4% of people with Type 1 diabetes and
50.8% with Type 2 diabetes reported a hypoglycaemic event.
The estimated global annual rate of any hypoglycaemia was
51.5 (95% CI 50.9–52.1) episodes for people with Type 1
diabetes and 16.5 (95% CI 16.3–16.7) episodes for Type 2
diabetes (Table 1). Prospectively, the percentages of partic-
ipants experiencing hypoglycaemic events were similar to
those reported retrospectively: 83.0% with Type 1 diabetes
and 46.5% with Type 2 diabetes. However, the estimated
global annual rates of any hypoglycaemia in the prospective
period were significantly higher than in the retrospective
period for Type 1 diabetes [rate ratio (RR) prospective/
retrospective: 1.47, 95% CI 1.41–1.53; P < 0.001) and Type
2 diabetes (RR prospective/retrospective: 1.20, 95% CI
1.15–1.24; P < 0.001).
Reported rates of severe hypoglycaemia were consistently
higher for the prospective vs. the retrospective period
(Table 1). Overall, in Type 1 diabetes, there was no
significant difference in the prospective/retrospective rates
(RR: 1.13, 95% CI 0.99–1.22), but in Type 2 diabetes the
rate was significantly lower retrospectively (RR: 1.19, 95%
CI 1.07–1.32; P < 0.001). The greatest increase in severe
hypoglycaemia incidence reported for the prospective vs.
retrospective period was in Latin America for both Type 1
and Type 2 diabetes.
During the 6-month retrospective period, 381 (4.8%)
people with Type 1 diabetes and 673 (3.5%) with Type 2
diabetes experienced severe hypoglycaemia requiring hospi-
tal admission. In comparison, during the 4-week prospec-
tive period, 116 (1.7%) people with Type 1 diabetes and
265 (1.5%) people with Type 2 diabetes experienced severe
hypoglycaemia requiring hospital admission. The rates of
severe hypoglycaemia requiring hospitalization were higher
in the prospective vs. retrospective period for Type 1 and
Type 2 diabetes for the overall population and across
regions (Table 1).
Hypoglycaemia rates: regional differences in the prospective
period
For the prospective period, the highest rates of any hypogly-
caemia for Type 1 diabetes were reported in Northern
Europe/Canada and Latin America, and the lowest were in
South East Asia; the rates for Type 2 diabetes were highest in
Russia and lowest in South East Asia (Table 1) [13].
In the prospective period, the regions with the highest
confirmed symptomatic hypoglycaemia rates were Northern
Europe/Canada and Eastern Europe for Type 1 and Type 2
diabetes, respectively (Table 1). The lowest rate of confirmed
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symptomatic hypoglycaemia was in South East Asia for both
Type 1 and Type 2 diabetes (Table 1).
For the prospective period, the highest rates of severe
hypoglycaemia for Type 1 and Type 2 diabetes were reported
in Latin America, with the lowest rates in South East Asia for
Type 1 diabetes and Northern Europe/Canada for Type 2
diabetes (Table 1) [13]. The rate of severe hypoglycaemia
leading to hospital admission was highest in Latin America
for both Type 1 and Type 2 diabetes, and lowest in Eastern
Europe and Russia for Type 1 diabetes and Russia for Type 2
diabetes (Table 1).
Hypoglycaemia incidence and frequency of blood glucose
monitoring
In most regions (with the exception of South East Asia), there
was a trend towards greater frequency of blood glucose
monitoring with greater prevalence and incidence of hypo-
glycaemia in participants with Type 1 diabetes. The percent-
age of participants with Type 1 diabetes experiencing
hypoglycaemia was lowest among those in the first quartile
for frequency of blood glucose monitoring in Latin America
(14.3%), and highest among those in the fourth quartile for
in Latin America (90.0%). Similarly (with the exception of
South East Asia), participants with Type 1 diabetes in the
first quartile for blood glucose monitoring in Latin America
reported the lowest incidence of hypoglycaemia [estimated
annual incidence rate (IR) 7.45, 95% CI 2.03–19.09] and
those in the fourth quartile reported the highest incidence (IR
91.31, 95% CI 85.48–97.44). There was no clear trend
between incidence of hypoglycaemia and frequency of blood
glucose monitoring in participants with Type 1 diabetes in
South East Asia.
In Type 2 diabetes, the percentage of participants reporting
hypoglycaemia was lowest in those in the first quartile for
blood glucose monitoring in the Middle East (11.2%) and
highest for those in the fourth quartile in Eastern Europe
(67.0%). The incidence of hypoglycaemia was also lowest
for those with Type 2 diabetes in the first quartile for blood
glucose monitoring frequency in the Middle East (IR 2.67,
95% CI 2.05–3.41) and highest for participants in Latin
America in the fourth quartile (IR 29.20, 95% CI 24.58–
34.31). There was no clear trend between the prevalence or
incidence of hypoglycaemia and frequency of blood glucose
monitoring in participants with Type 2 diabetes in South
East Asia or Northern Europe/Canada.
Hypoglycaemia definitions
Most participants were familiar with the ADA/EASD defini-
tion of hypoglycaemia [16], but there were regional varia-
tions (Table 2). The highest percentage of participants
familiar with the ADA/EASD definition of hypoglycaemia
was in Eastern Europe for Type 1 diabetes and Russia for
Type 2 diabetes, whereas the lowest percentage was South
East Asia for both Type 1 and Type 2 diabetes (Table 2).
Overall, 49.1% of people with Type 1 diabetes and 42.3%
with Type 2 diabetes reported defining hypoglycaemia based
on both blood glucose measurements and symptoms,
whereas 26.8% and 35.6% of people with Type 1 and Type
2 diabetes, respectively, defined hypoglycaemia in the
participant diary by symptoms alone (Fig. 1). The region
with the highest proportion of participants defining hypo-
glycaemia by symptoms alone was South East Asia for Type
1 diabetes and Russia for Type 2 diabetes, compared with the
lowest proportions in Northern Europe/Canada for both
Type 1 and Type 2 diabetes (Fig. 1).
Globally, the mean (SD) blood glucose concentration cut-
off below which participants considered (or defined) hypo-
glycaemia to have occurred was 3.4 (0.75) and 3.6
(0.82) mmol/l for Type 1 and Type 2 diabetes, respectively.
However, there were wide regional differences, and differ-
ences between populations with Type 1 and Type 2 diabetes
from the same region (Table 3). In general, people with Type
1 diabetes defined hypoglycaemia to have occurred at a lower
blood glucose level than people with Type 2 diabetes from
the same region. Among those with Type 1 diabetes, the
lowest mean blood glucose cut-off at which participants
defined a hypoglycaemic event to have occurred was
3.1 mmol/l (South East Asia) and the highest was
3.6 mmol/l (Russia). In Type 2 diabetes, the lowest defined
blood glucose cut-off was 3.5 mmol/l (Northern Europe/
Canada) and the highest was 3.8 mmol/l (Russia). Overall,
hypoglycaemia rates were lowest in South East Asia for all
hypoglycaemia definitions and the mean blood glucose
definition for Type 1 diabetes (but not Type 2 diabetes)
was the lowest for this region. The region with the highest
mean blood glucose definition for Type 2 diabetes (Russia)
Table 2 Percentage of participants familiar with the American Diabetes Association/European Association for the Study of Diabetes definition of
hypoglycaemia by region
Global
Northern
Europe/Canada
Eastern
Europe
Latin
America
Middle
East Russia
South
East Asia
Type 1 diabetes 96.8 95.8 98.1 95.8 96.5 98.0 91.6
Type 2 diabetes 85.6 83.4 92.2 80.1 86.8 93.4 76.7
Percentages are based on the number of participants with evaluable data.
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was also the region with the highest rate of any hypogly-
caemia, whereas the region with the lowest mean blood
glucose definition for Type 1 diabetes (South East Asia) had
the lowest rates of any and confirmed symptomatic hypo-
glycaemia. Across the other regions, the blood glucose cut-
off used to define hypoglycaemia did not appear to correlate
with the rate of ‘any’ or confirmed symptomatic hypogly-
caemia.
Stratifying the blood glucose definition according to
gender or whether a participant was aware of the ADA/
EASD hypoglycaemia definition did not have a substantial
effect on the results (Table 3), suggesting that these two
factors did not influence how participants define hypogly-
caemia. When blood glucose definitions were stratified
according to duration of diabetes, there was a trend towards
a lower blood glucose threshold being used by participants
with Type 1 diabetes with a longer duration of diabetes (> 10
vs. < 5 or 5–10 years) in each region, with the exception of
Russia where the lowest blood glucose definition was used by
those with a diabetes duration of 5–10 years (Table 3).
Stratifying the blood glucose definitions according to the
participants’ levels of hypoglycaemia awareness revealed a
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FIGURE 1 Definitions of hypoglycaemia used in the participant diary by participants with (a) Type 1 diabetes and (b) Type 2 diabetes.
BG, blood glucose.
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trend towards lower blood glucose definitions being used by
people with Type 1 diabetes with severely impaired hypo-
glycaemia awareness, with the exception of Russia where the
lowest blood glucose definition was used by those with Type
1 diabetes and normal hypoglycaemia awareness. There was
no clear trend across the regions in the blood glucose
definition used by people with Type 2 diabetes when
stratified according to duration of diabetes or hypoglycaemia
awareness.
To further investigate these regional differences and why,
despite being familiar with the global hypoglycaemia defini-
tion, participants define their hypoglycaemia with a different
blood glucose cut-off, the blood glucose level at which
hypoglycaemia symptoms were perceived by participants was
stratified according to HbA1c and diabetes duration for three
of the countries included in the study having different ethnic
populations: India (considered to be a largely homogeneous
population), Malaysia (considered to be a heterogeneous
population) and Canada (which has a large Asian popula-
tion) (Table 4). In these countries, there was no clear
correlation between HbA1c or diabetes duration with the
hypoglycaemia blood glucose cut-off at which symptoms
were perceived.
Discussion
In this analysis, a high proportion of participants involved in
the global HAT study responded that they were familiar with
the ADA/EASD definition of hypoglycaemia. However, there
were regional variations in the way hypoglycaemia was
typically defined by participants (symptomatic vs. blood
glucose measurement) and in the blood glucose cut-off used.
These differences can make comparing hypoglycaemia rates
between countries difficult. Regional discrepancies between
participant definitions and the consensus guidelines may
highlight a need to redefine the criteria of hypoglycaemia
Table 3 Blood glucose measurement below which participants defined hypoglycaemic events in the 4 weeks pre-baseline
Global
Northern
Europe/Canada
Eastern
Europe
Latin
America
Middle
East Russia
South
East Asia
Overall population, mmol/l
Type 1 diabetes 3.4 (0.75) 3.3 (0.71) 3.4 (0.72) 3.5 (0.71) 3.5 (0.83) 3.6 (0.77) 3.1 (1.04)
Type 2 diabetes 3.6 (0.82) 3.5 (0.80) 3.6 (0.81) 3.6 (0.77) 3.7 (0.84) 3.8 (0.89) 3.7 (0.85)
Grouped by sex, mmol/l
Type 1 diabetes
Male 3.4 (0.72) 3.3 (0.73) 3.4 (0.69) 3.5 (0.63) 3.5 (0.76) 3.5 (0.71) 3.3 (0.86)
Female 3.4 (0.77) 3.3 (0.70) 3.4 (0.74) 3.4 (0.75) 3.5 (0.89) 3.6 (0.81) 3.1 (1.14)
Type 2 diabetes
Male 3.6 (0.80) 3.5 (0.80) 3.6 (0.78) 3.6 (0.75) 3.7 (0.82) 3.7 (0.85) 3.7 (0.82)
Female 3.6 (0.84) 3.5 (0.79) 3.6 (0.83) 3.5 (0.78) 3.7 (0.87) 3.9 (0.90) 3.6 (0.89)
Grouped according to knowledge of ADA/EASD definition of hypoglycaemia, mmol/l
Type 1 diabetes
Knew definition 3.4 (0.74) 3.3 (0.70) 3.4 (0.71) 3.5 (0.70) 3.5 (0.83) 3.6 (0.77) 3.1 (1.04)
Did not know definition 3.4 (0.98) 3.5 (1.13) 3.3 (0.81) 3.5 (1.07) 3.5 (1.03) 3.5 (0.69) N/C
Type 2 diabetes
Knew definition 3.6 (0.81) 3.5 (0.78) 3.6 (0.80) 3.6 (0.76) 3.7 (0.82) 3.8 (0.88) 3.6 (0.85)
Did not know definition 3.7 (0.96) 3.5 (0.93) 3.6 (0.95) 3.6 (0.90) 4.0 (1.21) 3.5 (1.04) 4.0 (0.77)
Grouped by duration of diabetes, mmol/l
Type 1 diabetes
<5 years 3.5 (0.62) 3.4 (0.69) 3.4 (0.58) 3.6 (0.59) 3.6 (0.63) 3.5 (0.63) 3.2 (0.58)
5–10 years 3.4 (0.70) 3.4 (0.63) 3.4 (0.68) 3.5 (0.64) 3.5 (0.84) 3.4 (0.67) 3.2 (0.89)
>10 years 3.3 (0.78) 3.2 (0.73) 3.3 (0.75) 3.4 (0.75) 3.5 (0.86) 3.6 (0.82) 3.1 (1.20)
Type 2 diabetes
<5 years 3.6 (0.79) 3.7 (0.77) 3.5 (0.69) 3.5 (0.73) 3.6 (1.06) 3.6 (0.80) 3.9 (0.88)
5–10 years 3.6 (0.83) 3.5 (0.82) 3.6 (0.81) 3.6 (0.79) 3.6 (0.81) 3.7 (0.84) 3.7 (0.87)
>10 years 3.6 (0.82) 3.5 (0.79) 3.6 (0.81) 3.6 (0.77) 3.7 (0.83) 3.9 (0.92) 3.6 (0.81)
Grouped by hypoglycaemia awareness*, mmol/l
Type 1 diabetes
Normal 3.4 (0.76) 3.3 (0.69) 3.4 (0.73) 3.5 (0.70) 3.6 (0.90) 3.5 (0.74) 3.1 (1.45)
Impaired 3.4 (0.69) 3.3 (0.69) 3.4 (0.63) 3.5 (0.74) 3.5 (0.73) 3.6 (0.77) 3.4 (0.82)
Severely impaired 3.2 (0.83) 3.1 (0.83) 3.2 (0.83) 3.3 (0.67) 3.4 (0.83) 3.7 (0.86) 3.0 (0.83)
Type 2 diabetes
Normal 3.6 (0.83) 3.5 (0.79) 3.6 (0.82) 3.6 (0.80) 3.7 (0.87) 3.7 (0.85) 3.6 (0.91)
Impaired 3.6 (0.78) 3.5 (0.79) 3.6 (0.74) 3.6 (0.70) 3.6 (0.80) 4.0 (0.86) 3.8 (0.78)
Severely impaired 3.6 (0.85) 3.6 (0.83) 3.6 (0.86) 3.6 (0.76) 3.7 (0.81) 3.9 (1.00) 3.6 (0.87)
*The categories of ‘hypoglycaemia awareness’ correspond to answers given to the question ‘Do you have symptoms when you have a low
sugar level?’, where ‘Always’ denotes normal, ‘Usually’ denotes impaired, and ‘Occasionally’ and ‘Never’ denote severely impaired
awareness. Data are mean (SD).
ADA, American Diabetes Association; EASD, European Association for the Study of Diabetes; N/C, not calculable (0 participants in this
group).
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and/or the need to increase education. People with diabetes
in developing countries may be less likely to have access to
blood glucose-testing devices/materials, making them more
reliant on diagnosis of hypoglycaemia by symptoms alone.
This is supported by the lower reporting of hypoglycaemia in
regions such as South East Asia and may also reflect lower
levels of communication and/or reporting of hypoglycaemia
to healthcare professionals. The study population in North-
ern Europe/Canada had a longer disease duration and had
used insulin for longer than the other regions, which might
influence the level of hypoglycaemia awareness. For the
overall HAT study population, HbA1c was not found to be a
significant predictor of hypoglycaemia [13]. However, in
people with Type 2 diabetes, the higher blood glucose cut-off
for defining hypoglycaemia occurred in regions with a higher
mean HbA1c (Middle East, Russia and South East Asia),
perhaps suggesting that these participants experience hypo-
glycaemia at higher blood glucose levels. Further under-
standing of these regional differences could help to better
optimize therapies for particular populations. Regional
differences may also be a consequence of physiological
differences between ethnic groups regarding the level at
which individuals experience the symptoms of hypogly-
caemia, e.g. pseudohypoglycaemia; however, this needs
further investigation. Furthermore, it is possible that there
are additional between-country differences in the incidence
and reporting of hypoglycaemia within the regions described
here – this could be investigated in further analyses of these
data.
The results provide important information on the inci-
dence of hypoglycaemia in people with diabetes and show
that rates are higher than many previous estimates, partic-
ularly those reported from randomized clinical trials [13].
The HAT study also provides regional data from many areas
without previous information on hypoglycaemia and indi-
cates that rates of hypoglycaemia vary considerably between
countries. Furthermore, this analysis shows that the rates of
any and severe hypoglycaemia were lower in the retrospec-
tive compared with the prospective study period, suggesting
that hypoglycaemia may often be under-reported. This is
supported by a previous European study, which showed that
65% of people with Type 1 diabetes and 50–59% of those
with Type 2 diabetes frequently did not discuss hypogly-
caemia with their physicians [18]. We observed the greatest
differences between retrospective and prospective rates of
hypoglycaemia in the Latin America cohort, suggesting
under-reporting may be especially prevalent there.
The limitations of this study include potential participant-
selection bias (due to participation in the observational
study), the short duration of the prospective period and bias
resulting from data collection based on participant recall,
which may not be accurate, particularly for the retrospective
period. A true rate of hypoglycaemia can only be obtained
using continuous glucose monitoring, which was not possible
in a study of this scale. Data were not available regarding the
previous level of diabetes knowledge of the study partici-
pants, and this may have influenced the likelihood of
recognizing and reporting retrospective hypoglycaemic
events, prior to receiving information as a part of the study.
During the prospective period, it is possible that participants
were primed to look for hypoglycaemia, and therefore rates
may be overestimated or differences over-interpreted, which
may differ according to ethnicity. Data were not collected on
the frequency of blood glucose testing during the prospective
period, unless in connection with a hypoglycaemic event –
this may introduce a further bias as access to blood glucose-
testing devices/materials may vary, and those who test blood
glucose more frequently may be more likely to notice and
Table 4 Blood glucose levels at which hypoglycaemia symptoms are perceived, by country
Stratification
India Malaysia Canada
Type 1 diabetes
(n = 112)
Type 2 diabetes
(n = 2808)
Type 1 diabetes
(n = 114)
Type 2 diabetes
(n = 1039)
Type 1 diabetes
(n = 183)
Type 2 diabetes
(n = 315)
HbA1c, no. of participants, mean mmol/l (SD)
<53 mmol/mol (7%) n = 2
2.9 (0.55)
n = 39
3.4 (0.80)
n = 14
3.2 (0.80)
n = 56
3.4 (0.65)
n = 32
3.6 (0.71)
n = 43
3.7 (0.55)
53–64 mmol/mol (7–8%) n = 15
3.6 (0.83)
n = 246
3.8 (0.77)
n = 20
3.0 (0.81)
n = 147
3.8 (0.97)
n = 69
3.6 (0.74)
n = 75
3.6 (0.75)
>64 mmol/mol (8%) n = 17
3.2 (0.75)
n = 395
3.6 (0.80)
n = 45
3.1 (1.33)
n = 275
3.7 (0.96)
n = 56
3.5 (0.69)
n = 95
3.7 (0.92)
Duration of diabetes, no. of participants, mean mmol/l (SD)
<5 years n = 8
3.1 (0.74)
n = 93
3.9 (0.88)
n = 16
3.2 (0.50)
n = 46
3.8 (0.88)
n = 20
3.6 (0.53)
n = 17
3.7 (0.60)
5–10 years n = 9
3.5 (0.87)
n = 384
3.7 (0.79)
n = 17
3.1 (0.90)
n = 190
3.8 (1.03)
n = 28
3.6 (0.68)
n = 55
3.6 (0.65)
>10 years n = 24
3.3 (0.83)
n = 350
3.5 (0.73)
n = 52
3.0 (1.33)
n = 310
3.6 (0.89)
n = 121
3.5 (0.73)
n = 158
3.6 (0.84)
Analysis based on participants who reported self-measured blood glucose and symptoms.
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report low blood glucose. Additionally, the definition of
hypoglycaemia selected was subjective and, as nocturnal
hypoglycaemia included any event occurring between mid-
night and 06:00 h, this may have included events when
participants were not asleep (for example, in shift workers).
The cohort size varied between regions and was, for
example, smaller for South East Asia compared with the
other regions, increasing the potential for selection bias.
Within the geographical regions analysed, there was consid-
erable population heterogeneity (nationalities/ethnicity).
Data were not collected on the type of insulin used or the
number of injections per day, both of which may impact
upon the rate of hypoglycaemia.
There are also strengths to our study. The HAT study
benefits from its size (it is the largest observational study of
hypoglycaemia to date), global study population and obser-
vational design, meaning the participant population are
likely to provide a better representation of clinical practice
vs. clinical trials. Furthermore, HAT included countries/
regions with little or no other previous data on hypogly-
caemia and utilized an encompassing definition of hypogly-
caemia (symptomatic episodes and those confirmed by a
blood glucose measurement collected using participant
diaries).
In conclusion, hypoglycaemia rates were higher than
previous estimates, suggesting hypoglycaemia is under-
reported, particularly with retrospective recall. Although
the rates of severe and non-severe hypoglycaemia differed
between geographical regions, regional variations in the
definition and reporting of hypoglycaemia may also con-
tribute to the global variations reported in the HAT study.
Discrepancies between participant definitions and guidelines
highlight a need to redefine hypoglycaemia criteria. Indeed, a
recent ADA/EASD position statement agreed that clinical
trials should report a glucose level of < 3.0 mmol/l, which is
sufficiently low to indicate serious, clinically important
hypoglycaemia [10]; it remains to be seen whether this will
be universally adopted.
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